BioVie Inc.
BIVINASDAQHealthcare● Active
$1.67
+$0.07(+4.38%)
Market Cap$12594871
P/E Ratio—
52W High$12.1
52W Low$1.06
BioVie Inc. (BIVI) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
BIVI · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 11, 2026EPS Actual
-$0.70
Est. -$0.73 · +4.1%
Revenue
—
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 11, 2026
After Market Close
▲ Beat EPS✓ 2-Quarter EPS Beat Streak
BIVI reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$0.09
Rev. $41.31B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$0.09
Rev. Est.$41.31B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Sep 2, 2026 | -$0.52 | — | — | — | — | — |
| ◌ Q3 FY2026 | Sep 2, 2026 | -$0.52 | — | — | — | — | — |
| ▲ Q2 FY2026 | May 11, 2026 | -$0.73 | -$0.70 | +4.1% | — | — | — |
| ▲ Q1 FY2026 | Feb 6, 2026 | -$0.81 | -$0.77 | +4.9% | — | — | — |
| ▼ Q4 FY2025 | Nov 10, 2025 | -$0.79 | -$0.98 | -24.1% | — | — | — |
| ▲ Q3 FY2025 | Aug 15, 2025 | -$4.40 | -$0.24 | +94.6% | — | — | — |
| ▲ Q2 FY2025 | May 12, 2025 | -$3.20 | -$1.50 | +53.1% | — | — | — |
| ▲ Q1 FY2025 | Feb 11, 2025 | -$16.00 | -$4.60 | +71.3% | — | — | — |
Q3 FY2026
Sep 2, 2026
EPS Actual
—
EPS Est.
-$0.52
EPS Surpr.
—
Revenue
—
Q3 FY2026
Sep 2, 2026
EPS Actual
—
EPS Est.
-$0.52
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 11, 2026Beat
EPS Actual
-$0.70
EPS Est.
-$0.73
EPS Surpr.
+4.1%
Revenue
—
Q1 FY2026
Feb 6, 2026Beat
EPS Actual
-$0.77
EPS Est.
-$0.81
EPS Surpr.
+4.9%
Revenue
—
Q4 FY2025
Nov 10, 2025Miss
EPS Actual
-$0.98
EPS Est.
-$0.79
EPS Surpr.
-24.1%
Revenue
—
Q3 FY2025
Aug 15, 2025Beat
EPS Actual
-$0.24
EPS Est.
-$4.40
EPS Surpr.
+94.6%
Revenue
—
Q2 FY2025
May 12, 2025Beat
EPS Actual
-$1.50
EPS Est.
-$3.20
EPS Surpr.
+53.1%
Revenue
—
Q1 FY2025
Feb 11, 2025Beat
EPS Actual
-$4.60
EPS Est.
-$16.00
EPS Surpr.
+71.3%
Revenue
—
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q2 FY2026 | $-0.52 | $-0.52 | $-0.52 | 1 |
| Q1 FY2026 | $-0.73 | $-0.73 | $-0.73 | 1 |
| Q4 FY2025 | $-0.81 | $-0.81 | $-0.81 | 1 |
| Q3 FY2025 | $-0.98 | $-0.98 | $-0.98 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q2 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
| Q1 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
| Q4 FY2025 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2025 | $0.0B | $0.0B | $0.0B | 0 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | May 11, 2026 | +4.1% | $1.47 | $1.35 | -8.16% |
| ▲ Q1 FY2026 | Feb 6, 2026 | +4.9% | $1.06 | $1.13 | +6.60% |
| ▼ Q4 FY2025 | Nov 10, 2025 | -24.1% | $1.48 | $1.56 | +5.41% |
| ▲ Q3 FY2025 | Aug 15, 2025 | +94.6% | $1.66 | $1.65 | -0.60% |
| ▲ Q2 FY2025 | May 12, 2025 | +53.1% | $11.20 | $11.50 | +2.68% |
| ▲ Q1 FY2025 | Feb 11, 2025 | +71.3% | $18.60 | $18.00 | -3.23% |
| ▲ Q4 FY2024 | Nov 13, 2024 | +56.3% | $33.50 | $34.10 | +1.79% |
| ▼ Q3 FY2024 | Sep 30, 2024 | -340.0% | $12.00 | $12.00 | +0.00% |
Q2 FY2026-8.16%
Report Date
May 11, 2026
EPS Beat/Miss
+4.1%
Price Before
$1.47
Price After
$1.35
Q1 FY2026+6.60%
Report Date
Feb 6, 2026
EPS Beat/Miss
+4.9%
Price Before
$1.06
Price After
$1.13
Q4 FY2025+5.41%
Report Date
Nov 10, 2025
EPS Beat/Miss
-24.1%
Price Before
$1.48
Price After
$1.56
Q3 FY2025-0.60%
Report Date
Aug 15, 2025
EPS Beat/Miss
+94.6%
Price Before
$1.66
Price After
$1.65
Q2 FY2025+2.68%
Report Date
May 12, 2025
EPS Beat/Miss
+53.1%
Price Before
$11.20
Price After
$11.50
Q1 FY2025-3.23%
Report Date
Feb 11, 2025
EPS Beat/Miss
+71.3%
Price Before
$18.60
Price After
$18.00
Q4 FY2024+1.79%
Report Date
Nov 13, 2024
EPS Beat/Miss
+56.3%
Price Before
$33.50
Price After
$34.10
Q3 FY2024+0.00%
Report Date
Sep 30, 2024
EPS Beat/Miss
-340.0%
Price Before
$12.00
Price After
$12.00
Avg Beat Reaction-0.15%
Avg Miss Reaction+2.71%
Beat Rate6 / 8 quarters
Largest Move-8.16% (Q2 FY2026)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: BIVI ends December
BioVie Inc. (BIVI) most recently reported earnings on May 11, 2026 for Q2 FY2026, posting EPS of $-0.70 — beating the analyst consensus of $-0.73 by +4.1%. BIVI has beaten EPS estimates for 2 consecutive quarters. The next BIVI earnings date is expected around September 1, 2026.
Each quarter, investors track BIVI earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. BIVI revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
BIVI's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
BIVI earnings · 5 questionsBioVie Inc.'s next earnings report is expected around September 1, 2026. BIVI typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; BIVI historically reports after market close (AMC).
BIVI earnings datewhen is BIVI earningsBIVI next earnings datewhen does BIVI report earningsBIVI earnings calendar
▸ Source: FMP · BioVie Inc. SEC filings · US GAAP · BioVie Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026